scispace - formally typeset
L

Liang-Bo Wang

Researcher at Washington University in St. Louis

Publications -  25
Citations -  2662

Liang-Bo Wang is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 13, co-authored 19 publications receiving 1340 citations. Previous affiliations of Liang-Bo Wang include National Taiwan University & Microsoft.

Papers
More filters
Journal ArticleDOI

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

David J. Clark, +224 more
- 31 Oct 2019 - 
TL;DR: A large-scale proteogenomic analysis of ccRCC is reported to discern the functional impact of genomic alterations and provides evidence for rational treatment selection stemming fromccRCC pathobiology.
Journal ArticleDOI

Large scale tissue histopathology image classification, segmentation, and visualization via deep convolutional activation features.

TL;DR: The framework proposed is a simple, efficient and effective system for histopathology image automatic analysis that successfully transfer ImageNet knowledge as deep convolutional activation features to the classification and segmentation of histopathological images with little training data.
Journal ArticleDOI

The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution

Orit Rozenblatt-Rosen, +373 more
- 16 Apr 2020 - 
TL;DR: The Human Tumor Atlas Network (HTAN), part of the NCI Cancer Moonshot Initiative, will establish a clinical, experimental, computational, and organizational framework to generate informative and accessible three-dimensional atlases of cancer transitions for a diverse set of tumor types.
Journal ArticleDOI

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Michael A. Gillette, +189 more
- 09 Jul 2020 - 
TL;DR: Comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK.